This article first appeared on GuruFocus .
-
Group Sales Revenue:Increased by 7.7% on an operational basis in constant currencies for H1 2026.
-
Bioprocess Solutions Growth:8.3% growth on an operational basis in constant currencies.
-
Lab Products and Services Growth:5.3% increase on an operational basis in constant currencies.
-
Underlying EBITDA Margin:Improved to 30.3% at the Group level.
-
Free Cash Flow:Increased by more than 70% to EUR208 million.
-
Net Debt to Underlying EBITDA Ratio:Improved to 3.51 times from 3.55 times at year-end 2025.
-
Underlying Net Profit:Increased by 2% to EUR172 million.
-
CapEx Ratio:8.9%, slightly below the prior year level.
-
Americas Sales Growth:5.6% on an operational basis, affected by tariff surcharges.
-
Asia Pacific Sales Growth:12.1% in constant currencies, supported by recovery in China.
-
Warning! GuruFocus has detected 10 Warning Signs with SARTF.
-
Is SARTF fairly valued? Test your thesis with our free DCF calculator.
Release Date: July 23, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Sartorius AG ( SARTF ) reported solid top-line growth with group sales revenues increasing by 7.7% on an operational basis in H1 2026.
-
The company improved its profitability, with the underlying EBITDA margin increasing to 30.3%.
-
Strong cash flow generation was noted, with free cash flow significantly up by 70% in H1.
-
The Bioprocessing Solutions division delivered 8.3% growth on an operational basis, driven by consumables.
-
Sartorius AG ( SARTF ) maintained a strong balance sheet, with the equity ratio increasing to 41.6% at the end of June 2026.
Negative Points
-
The equipment business showed only slight growth, around 2%, indicating a slower recovery compared to consumables.
-
Tariff-related customer compensations created a temporary headwind to reported sales growth, impacting the overall revenue figures.
-
The company faced some volatility in advanced modalities due to delayed orders from two major customers.
-
The Americas region experienced a decline in sales on a nominal basis, affected by customer compensations for tariff surcharges.
-
The Lab Products and Services division's growth was primarily driven by recurring business, with instruments business showing only slight growth.
Q & A Highlights
Q: Based on the underlying performance of BPS in the first half and your guidance, how is your confidence level in the 9% to 12% growth outlook for BPS in the coming years developing? A: Rene Faber, CEO of Sartorius Stedim Biotech, stated that the company sees ongoing solid growth in demand for commercial drugs, driving consumables growth. The healthy pipeline growth and approval rates, along with recovery in advanced modalities and better biotech funding, support double-digit growth of consumables. The company delivered slightly more than 9% consumables operational growth in H1 2026 and expects to continue this trajectory.
Q: Can you give us some color on the delayed programs and whether this will be a headwind in H2? A: Florian Funck, CFO of Sartorius AG, explained that the operational view includes the general surcharge as a fact of current business life, with a positive effect of 40 basis points on group growth. Rene Faber added that two key customers in advanced therapy delayed projects, impacting recurring revenue growth in H1 and potentially in the full year. However, the company remains confident in the market's long-term potential.
Q: Do you believe the issues with delayed revenue in advanced modalities are related to those experienced by Danaher with monoclonal antibody customers? A: Michael Grosse, CEO of Sartorius AG, clarified that the issues are not related. The delays were isolated to two customers in the advanced therapy space, and there is no implication for the classical protein-based portfolio.
Q: What metrics support your confidence in strong underlying demand within BPS consumables and double-digit growth continuing? A: Michael Grosse highlighted that growth is supported by large CDMO and biopharma customers in late-stage or commercial production. The visibility and outlook for classical protein-based therapies and some advanced therapies are strong, supporting the continuation of the growth journey.
Q: Could you share additional detail on why bioprocessing product groups within equipment and consumables have been relatively weaker in terms of mix? A: Florian Funck explained that the mix effect is not classical, like recurring versus non-recurring, but rather within different product categories. Delayed projects in advanced therapy systems, which come with high margins, are a driver of the negative mix effect.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
